Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on May 19, 2017, 10:45:00 am

Title: Gilead’s NASH Drug Shows Promise in Early Trial
Post by: Hep Editors on May 19, 2017, 10:45:00 am

Gilead Sciences’ GS-0976 improved multiple measures of liver health in a small study of those with non-alcoholic steatohepatitis (NASH) in an open-label, proof-of-concept study.

Researchers recruited 10 people with NASH and gave them 20 milligrams of GS-0967, an investigational inhibitor of Acetyl-CoA carboxylase (ACC), to be taken orally once daily for 12 weeks.

Findings were presented at the 52nd International Liver Congress in Amsterdam.

For more...
https://www.hepmag.com/article/gileads-nash-drug-shows-promise-early-trial